Decoding F508del Misfolding in Cystic Fibrosis

被引:10
|
作者
Wang, Xiaodong Robert [1 ]
Li, Chenglong [2 ]
机构
[1] Samford Univ, McWhorter Sch Pharm, Dept Pharmaceut, Social & Adm Sci, 800 Lakeshore Dr, Birmingham, AL 35229 USA
[2] Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, Columbus, OH 43210 USA
来源
BIOMOLECULES | 2014年 / 4卷 / 02期
关键词
ABC transporter; CFTR; cystic fibrosis; drug discovery; F508del; molecular dynamics simulation; nucleotide-binding domain; protein conformation; protein folding; protein stability;
D O I
10.3390/biom4020498
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The functional deficiency of the cystic fibrosis transmembrane conductance regulator (CFTR), a plasma membrane chloride channel, leads to the development of cystic fibrosis. The deletion of a phenylalanine at residue 508 (F508del) is the most common cause of CFTR misfolding leading to the disease. The F508del misfolding originates in the first nucleotide-binding domain (NBD1), which induces a global conformational change in CFTR through NBD1's interactions with other domains. Such global misfolding produces a mutant chloride channel that is impaired in exocytic trafficking, peripheral stability, and channel gating. The nature and atomic details of F508del misfolding have been subject to extensive research during the past decade. Current data support a central role for NBD1 in F508del misfolding and rescue. Many cis-acting NBD1 second-site mutations rescue F508del misfolding in the context of full-length CFTR. While some of these mutations appear to specifically counteract the F508del-induced misfolding, others release certain inherent conformational constraints of the human wild-type CFTR. Several small-molecule correctors were recently found to act on key interdomain interfaces of F508del CFTR. Potential rational approaches have been proposed in an attempt to develop highly effective small molecule modulators that improve the cell surface functional expression of F508del CFTR.
引用
收藏
页码:498 / 509
页数:12
相关论文
共 50 条
  • [1] Screening for F508del as a first step in the molecular diagnosis of cystic fibrosis
    de Lima Marson, Fernando Augusto
    Bertuzzo, Carmen Silvia
    Goncalves de Oliveira Ribeiro, Maria Angela
    Ribeiro, Antonio Fernando
    Ribeiro, Jose Dirceu
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2013, 39 (03) : 306 - 316
  • [2] The cystic fibrosis F508del mutation in Crohn's disease
    Bresso, Francesca
    D'Amato, Mauro
    JOURNAL OF CYSTIC FIBROSIS, 2011, 10 (02) : 132 - 132
  • [3] Carrier frequency of F508del mutation of cystic fibrosis in Indian population
    Kapoor, Vishal
    Shastri, Shivaram S.
    Kabra, Madhulika
    Sushil, Kumar Kabra
    Ramachandran, Vijaya
    Arora, Sadhna
    Prahlad, Balakrishnan
    Deorari, Ashok Kumar
    Paul, Vinod Kumar
    JOURNAL OF CYSTIC FIBROSIS, 2006, 5 (01) : 43 - 46
  • [4] Detection of the ΔF508 (F508del) mutation of the cystic fibrosis gene by surface plasmon resonance and biosensor technology
    Feriotto, G
    Lucci, M
    Bianchi, N
    Mischiati, C
    Gambari, R
    HUMAN MUTATION, 1999, 13 (05) : 390 - 400
  • [5] Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del
    Beswick, Daniel M.
    Humphries, Stephen M.
    Balkissoon, Connor D.
    Strand, Matthew
    Miller, Jessa E.
    Khatiwada, Aastha
    Vladar, Eszter K.
    Lynch, David A.
    Taylor-Cousar, Jennifer L.
    INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2022, 12 (07) : 963 - 966
  • [6] Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
    Comegna, Marika
    Terlizzi, Vito
    Salvatore, Donatello
    Colangelo, Carmela
    Di Lullo, Antonella Miriam
    Zollo, Immacolata
    Taccetti, Giovanni
    Castaldo, Giuseppe
    Amato, Felice
    ANTIBIOTICS-BASEL, 2021, 10 (07):
  • [7] Impact of lumacaf tor/ivacaf tor and tezacaf tor/ivacaf tor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis
    McElvaney, Oliver J.
    Heltshe, Sonya L.
    Odem-Davis, Katherine
    West, Natalie E.
    Sanders, Don B.
    Fogarty, Barbra
    VanDevanter, Donald R.
    Flume, Patrick A.
    Goss, Christopher H.
    JOURNAL OF CYSTIC FIBROSIS, 2023, 22 (05) : 875 - 879
  • [8] Effect of the F508del genotype on outcomes of endoscopic sinus surgery in children with cystic fibrosis
    Do, Bao Anh Julie
    Lands, Larry C.
    Saint-Martin, Christine
    Mascarella, Marco A.
    Manoukian, John J.
    Daniel, Sam J.
    Nguyen, Lily H. P.
    INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2014, 78 (07) : 1133 - 1137
  • [9] Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation
    Sawicki, Gregory S.
    Van Brunt, Kate
    Booth, Jason
    Bailey, Evan
    Millar, Stefanie J.
    Konstan, Michael W.
    Flume, Patrick A.
    JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (01) : 96 - 103
  • [10] Cystic fibrosis F508del carriers and cancer risk: Results from the UK Biobank
    Shi, Zhuqing
    Wei, Jun
    Na, Rong
    Resurreccion, W. Kyle
    Zheng, S. Lilly
    Hulick, Peter J.
    Helfand, Brian T.
    Talamonti, Mark S.
    Xu, Jianfeng
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (07) : 1658 - 1664